Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty).
Inhaled corticosteroids plus standard care showed no clear difference in infections compared with standard care (with or without placebo) (low certainty).
Effects of different inhaled corticosteroids on growth in children… may leads to higher linear growth velocity (cm/year) compared with beclomethasone (low certainty).
It is very uncertain whether effects of different inhaled corticosteroids on growth in children… changes linear growth velocity (cm/year) compared with budesonide (very low certainty).
Effects of different inhaled corticosteroids on growth in children… probably leads to higher change in height (cm) over a period of time compared with budesonide (moderate certainty).
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants cured.… compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants with P… compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
A boost of inhaled corticosteroids showed no clear difference in exacerbations compared with usual care (moderate certainty).
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
Subcutaneous omalizumab + steroid may leads to higher number of participants achieving complete inhaled steroid withdrawal… compared with placebo + steroid (steroid reduction) (low certainty).
Subcutaneous omalizumab + steroid probably leads to higher >50% reduction in inhaled steroid usage 28 to 32 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).